United Therapeutics (NASDAQ:UTHR) CEO Sells $5,079,270.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $534.66, for a total value of $5,079,270.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at $173,466,694.38. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $563.49 on Thursday. The company has a market capitalization of $24.17 billion, a PE ratio of 20.16, a P/E/G ratio of 3.96 and a beta of 0.49. The company has a 50 day simple moving average of $515.71 and a two-hundred day simple moving average of $539.59. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $6.41 EPS. Research analysts predict that United Therapeutics Corporation will post 26.40 EPS for the current year.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their outlook. Leerink Partners increased its price target for United Therapeutics to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus remains bullish, with a “Moderate Buy” rating and an average target near $650, implying further potential upside. Leerink Partners Raises Price Target
• Positive Sentiment: United Therapeutics expanded its xenograft capacity. The company opened its third designated pathogen-free xenograft production facility in Houston, Texas. The facility supports its longer-term strategy of developing genetically modified organs for transplantation and may strengthen future growth opportunities beyond its pulmonary hypertension drug franchise. Third Xenograft Production Facility
• Neutral Sentiment: Third-quarter earnings are approaching. United Therapeutics will report financial results before the market opens on November 4. The release could provide an important update on demand for Tyvaso and other pulmonary hypertension treatments, margins, and progress in organ manufacturing. Third-Quarter 2026 Earnings Announcement
• Negative Sentiment: Insider selling presents a modest cautionary signal. CEO Martine Rothblatt reported sales of 9,500 shares in transactions dated October 16 and October 19, reducing her position by about 2.84% in each filing. The company’s general counsel also sold shares under a trading plan. Because the sales appear relatively small compared with Rothblatt’s remaining stake and were conducted under planned arrangements, they do not necessarily indicate deteriorating business prospects.

Analyst Ratings Changes

Several equities analysts recently issued reports on UTHR shares. Raymond James Financial restated an “outperform” rating and issued a $717.00 target price on shares of United Therapeutics in a report on Tuesday. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $651.21.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Cardinal Capital Management increased its holdings in United Therapeutics by 0.5% during the 3rd quarter. Cardinal Capital Management now owns 12,033 shares of the biotechnology company’s stock worth $6,521,000 after purchasing an additional 63 shares in the last quarter. PFS Partners LLC purchased a new stake in United Therapeutics in the 3rd quarter valued at $45,000. Crossmark Global Holdings Inc. lifted its stake in United Therapeutics by 7.8% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 3,189 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 232 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in United Therapeutics by 1.1% during the 3rd quarter. Quadrant Capital Group LLC now owns 5,013 shares of the biotechnology company’s stock valued at $2,724,000 after acquiring an additional 54 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its stake in United Therapeutics by 18.8% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 146,163 shares of the biotechnology company’s stock valued at $79,204,000 after acquiring an additional 23,107 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.